Submit to Special Issue Submit Abstract to Special Issue Review for Biomedicines Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "State of the Art and Future Perspectives in Oncologic Imaging"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Therapeutics".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 2740

Share This Special Issue

Special Issue Editors

Dr. Adrien Holzgreve
E-Mail Website
Guest Editor

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
Interests: oncology; neuro-oncology; hybrid imaging; theranostics; translational research

Dr. Lena M. Unterrainer

E-Mail Website
Guest Editor

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
Interests: oncology; uro-oncology; hybrid imaging; theranostics; innovative tracers

Prof. Dr. Wolfgang Kunz

E-Mail Website
Guest Editor

Department of Radiology, University Hospital, LMU Munich, Munich, Germany
Interests: oncology; stroke; hybrid imaging; AI; health economics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Imaging has a fundamental role in oncology. Staging studies are indispensable for selecting a therapy or making a prognosis. Hardly any tumor surgery or radiotherapy is performed without prior image-guided planning. Likewise, we depend heavily on imaging to assess response to therapy. However, in contrast to its long-standing tradition in oncology, imaging is also one of the most exciting and dynamic fields: due to the constant relevance of imaging in the course of the disease, imaging is an omnipresent companion that mirrors the rapid and groundbreaking developments in the field of oncology. On the other hand, developments in the field of oncologic imaging are a genuine contributor to advances in the treatment of cancer patients. Thus, response criteria are based on imaging and are constantly refined, new theranostic targets can be addressed with the advances in imaging (e.g., using hybrid imaging techniques such as PET/CT or PET/MRI), and artificial intelligence imaging methods broaden the horizon even more.

The scope of this Special Issue is to reflect the double role of oncologic imaging as an established indispensable tool in clinical routine on the one hand, and as a thriving innovator pushing boundaries on the other. Therefore, we encourage the submission of articles both on state-of-the-art and future perspectives of oncologic imaging, including but not restricted to clinical and preclinical imaging studies and comprehensive reviews.

Kind regards,

Dr. Adrien Holzgreve
Dr. Lena M. Unterrainer
Prof. Dr. Wolfgang Kunz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

imaging response criteria
hybrid imaging
PET/CT
PET/MRT
immunotherapy
artificial intelligence
machine learning
radiomics
decision making
theranostics

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Diagnostic Impact of Dual-Time PET/CT with ⁶⁸Gallium-PSMA in Prostate Cancer and ⁶⁸Gallium-DOTATOC in Neuroendocrine Tumors

Damiano Librizzi

Friederike Eilsberger

and

Biomedicines 2023, 11(4), 1052; https://doi.org/10.3390/biomedicines11041052 - 29 Mar 2023

Viewed by 525

Abstract

Background: The timing of imaging for ⁶⁸gallium (⁶⁸Ga)-PSMA and ⁶⁸Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent ⁶⁸Ga-DOTATOC-PET/CT and 82 patients who underwent ⁶⁸Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all ⁶⁸Ga-DOTATOC cases and about one-third of all ⁶⁸Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For ⁶⁸Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with ⁶⁸Ga-DOTATOC and ⁶⁸Ga-PSMA PET/CT. Full article

(This article belongs to the Special Issue State of the Art and Future Perspectives in Oncologic Imaging)

► Show Figures

Figure 1

Open AccessArticle

Application of the American Thyroid Association Risk Assessment in Patients with Differentiated Thyroid Carcinoma in a German Population

Friederike Eilsberger

and

Biomedicines 2023, 11(3), 911; https://doi.org/10.3390/biomedicines11030911 - 15 Mar 2023

Viewed by 585

Abstract

Background: The American Thyroid Association (ATA) uses criteria to assess the risk for persistent disease in differentiated thyroid carcinoma (DTC) after radioiodine therapy (RAI). There are no data available showing that this classification can be adopted unadjusted by Germany. Aim: The aim of our study is to investigate whether the ATA classification can be applied to a German population for short-term prognosis. Furthermore, we investigated the influence of an age cutoff value. Methods: We retrospectively analyzed 121 patients who were referred to our tertiary referral center. Patients were classified into risk categories, and the therapy response was determined according to ATA. Results: A total of 73/83 (88%) ATA low-risk patients and 12/19 (63%) intermediate-risk patients showed an excellent response; 2/19 (11%) high-risk patients had a biochemical, and 6 (31%) had a structural incomplete response. Of all 39 patients ≥55 years, 84% had an excellent response. Using a cut off of 50 years, 50/62 (81%) of the older patients showed an excellent response. Conclusion: The ATA risk classification is able to estimate the response to RAI therapy in a German population. A shift from 55 to 50 years as an age cutoff value does not result in any relevant change in the treatment response. Full article

(This article belongs to the Special Issue State of the Art and Future Perspectives in Oncologic Imaging)

Open AccessArticle

Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters

Maria Ingenerf

Sophia Kiesl

Michael Winkelmann

Christoph J. Auernhammer

Johannes Rübenthaler

Freba Grawe

Matthias P. Fabritius

Jens Ricke

and

Christine Schmid-Tannwald

Biomedicines 2022, 10(10), 2618; https://doi.org/10.3390/biomedicines10102618 - 18 Oct 2022

Viewed by 629

Abstract

Assessment of treatment response to targeted therapies such as everolimus is difficult, especially in slow-growing tumors such as NETs. In this retrospective study, 17 patients with pancreatic neuroendocrine tumors (pNETs) and hepatic metastases (NELMs) (42 target lesions) who received everolimus were analyzed. Intralesional signal intensities (SI) of non-contrast T1w, T2w and DCE imaging, and apparent diffusion coefficients (ADCmean and ADCmin) of DWI, were measured on baseline and first follow-up MRI after everolimus initiation. Response assessment was categorized according to progression-free survival (PFS), with responders (R) showing a PFS of ≥11 months. ADCmin of NELMs decreased in Rs whereas it increased in non-responders (NR). Percentual changes of ADCmin and ADCmean differed significantly between response groups (p < 0.03). By contrast, ADC of the pNETs tended to increase in Rs, while there was no change in NRs. Tumor-to-liver (T/L) ratio of T1 SI of NELMs increased in Rs and decreased in NRs, and percentual changes differed significantly between response groups (p < 0.02). T1 SI of the pNETs tended to decrease in Rs and increase in Ns. The quotient of pretherapeutic and posttherapeutic ADCmin values (DADCmin) and length of everolimus treatment showed significant association with PFS in univariable Cox analysis. In conclusion, quantitative MRI, especially DWI, seems to allow treatment assessment of pNETs with NELMs under everolimus. Interestingly, the responding NELMs showed decreasing ADC values, and there might be an opposite effect on ADC and T1 SI between NELMs and pNETs. Full article

(This article belongs to the Special Issue State of the Art and Future Perspectives in Oncologic Imaging)

► Show Figures

Figure 1

Open AccessArticle

Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor

Friederike Eilsberger

Friederike Elisabeth Noltenius

and

Biomedicines 2022, 10(9), 2095; https://doi.org/10.3390/biomedicines10092095 - 27 Aug 2022

Viewed by 640

Abstract

Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. Methods: A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. Results: In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). Conclusion: FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease. Full article

(This article belongs to the Special Issue State of the Art and Future Perspectives in Oncologic Imaging)

► Show Figures

Journal Menu

Journal Browser

Special Issue "State of the Art and Future Perspectives in Oncologic Imaging"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI